Anand Parikh, Faeth Therapeutics CEO

Sid Mukher­jee, Lew Cant­ley be­hind new can­cer biotech with food+drug com­bo treat­ment am­bi­tions 

Famed on­col­o­gist Sid Mukher­jee and re­peat biotech co-founder Lew Cant­ley have teamed up to form Faeth Ther­a­peu­tics, a start­up aim­ing to treat can­cer the way oth­er con­di­tions are ad­dressed: pair­ing nu­tri­tion with ther­a­peu­tics.

The goal is to trans­form can­cer treat­ment with nu­tri­tion and make it the fourth “pil­lar” in the on­col­o­gy reg­i­men, which to date has cen­tered on ra­dio­ther­a­py, surgery and drugs, Faeth CEO Anand Parikh told End­points News. Oth­er con­di­tions have al­ready been ad­dressed with a side of nu­tri­ents or di­et, he said, point­ing to di­a­betes, ir­ri­ta­ble bow­el syn­drome and oth­er dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.